Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina

The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Urueña, Analía, Micone, Paula, Magneres, María Cecilia, Mould-Quevedo, Joaquín, Giglio, Norberto
Formato: Artículo
Lenguaje:Inglés
Publicado: 2024
Materias:
Influenza
Vacunas
Costo efectividad
Vacuna Trivalente contra la Influenza
Vacuna Cuadrivalente contra la Influenza
Acceso en línea:https://doi.org/10.3390/vaccines9040335
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2045
Aporte de:
Repositorio Institucional Digital (RID ISALUD) de Universidad ISALUD
id I92-R382-123456789-2045
record_format dspace
spelling I92-R382-123456789-20452024-10-31T06:00:56Z Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina Urueña, Analía Micone, Paula Magneres, María Cecilia Mould-Quevedo, Joaquín Giglio, Norberto Influenza Vacunas Costo efectividad Vacuna Trivalente contra la Influenza Vacuna Cuadrivalente contra la Influenza The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influenza season. Main outcomes included: numbers of influenza cases; general practitioner (GP) visits; complicated ambulatory cases; hospitalizations; deaths averted; and costs per quality-adjusted life years (QALYs) gained. Epidemiological data from Argentina for 2014–2019 were used to determine the proportion of A and B strain cases, and the frequency of mismatch between vaccine and circulating B strains. To manage uncertainty, one-way and probabilistic sensitivity analyses were performed. Switching from TIV to QIV would prevent 19,128 influenza cases, 16,164 GP visits, 2440 complicated ambulatory cases, 524 hospitalizations, and 82 deaths. Incremental cost–effectiveness ratios (ICERs) per QALY were 13,590 and 11,678 USD from the payer’s and societal perspectives, respectively. The greatest health benefits and direct medical cost savings would occur in ≥ 65-year-olds. One-way sensitivity analyses demonstrated the principal drivers of ICER to be vaccine acquisition costs, environmental B strain predominance, and B strain mismatch. Introducing QIV in Argentina would be beneficial and cost-effective relative to TIV, particularly in older adults. https://www.mdpi.com/2076-393X/9/4/335 Fil: Urueña A. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Venezuela 931, Ciudad Autónoma de Buenos Aires C1095AAS, Argentina Fil: Urueña A. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Venezuela 931, Ciudad Autónoma de Buenos Aires C1095AAS, Argentina 2024-10-30T20:43:19Z 2024-10-30T20:43:19Z 2022 Article Urueña A, Micone P, Magneres C, Mould-Quevedo J, Giglio N. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina. Vaccines. 2021; 9(4):335. https://doi.org/10.3390/vaccines9040335 https://doi.org/10.3390/vaccines9040335 http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2045 en application/pdf
institution Universidad ISALUD
institution_str I-92
repository_str R-382
collection Repositorio Institucional Digital (RID ISALUD)
language Inglés
topic Influenza
Vacunas
Costo efectividad
Vacuna Trivalente contra la Influenza
Vacuna Cuadrivalente contra la Influenza
spellingShingle Influenza
Vacunas
Costo efectividad
Vacuna Trivalente contra la Influenza
Vacuna Cuadrivalente contra la Influenza
Urueña, Analía
Micone, Paula
Magneres, María Cecilia
Mould-Quevedo, Joaquín
Giglio, Norberto
Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
topic_facet Influenza
Vacunas
Costo efectividad
Vacuna Trivalente contra la Influenza
Vacuna Cuadrivalente contra la Influenza
description The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influenza season. Main outcomes included: numbers of influenza cases; general practitioner (GP) visits; complicated ambulatory cases; hospitalizations; deaths averted; and costs per quality-adjusted life years (QALYs) gained. Epidemiological data from Argentina for 2014–2019 were used to determine the proportion of A and B strain cases, and the frequency of mismatch between vaccine and circulating B strains. To manage uncertainty, one-way and probabilistic sensitivity analyses were performed. Switching from TIV to QIV would prevent 19,128 influenza cases, 16,164 GP visits, 2440 complicated ambulatory cases, 524 hospitalizations, and 82 deaths. Incremental cost–effectiveness ratios (ICERs) per QALY were 13,590 and 11,678 USD from the payer’s and societal perspectives, respectively. The greatest health benefits and direct medical cost savings would occur in ≥ 65-year-olds. One-way sensitivity analyses demonstrated the principal drivers of ICER to be vaccine acquisition costs, environmental B strain predominance, and B strain mismatch. Introducing QIV in Argentina would be beneficial and cost-effective relative to TIV, particularly in older adults.
format Article
author Urueña, Analía
Micone, Paula
Magneres, María Cecilia
Mould-Quevedo, Joaquín
Giglio, Norberto
author_facet Urueña, Analía
Micone, Paula
Magneres, María Cecilia
Mould-Quevedo, Joaquín
Giglio, Norberto
author_sort Urueña, Analía
title Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
title_short Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
title_full Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
title_fullStr Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
title_full_unstemmed Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
title_sort cost-effectiveness analysis of switching from trivalent to quadrivalent seasonal influenza vaccine in argentina
publishDate 2024
url https://doi.org/10.3390/vaccines9040335
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2045
work_keys_str_mv AT uruenaanalia costeffectivenessanalysisofswitchingfromtrivalenttoquadrivalentseasonalinfluenzavaccineinargentina
AT miconepaula costeffectivenessanalysisofswitchingfromtrivalenttoquadrivalentseasonalinfluenzavaccineinargentina
AT magneresmariacecilia costeffectivenessanalysisofswitchingfromtrivalenttoquadrivalentseasonalinfluenzavaccineinargentina
AT mouldquevedojoaquin costeffectivenessanalysisofswitchingfromtrivalenttoquadrivalentseasonalinfluenzavaccineinargentina
AT giglionorberto costeffectivenessanalysisofswitchingfromtrivalenttoquadrivalentseasonalinfluenzavaccineinargentina
_version_ 1831499985943789568

Ejemplares similares